Suppr超能文献

移植肾后复发肾小球肾炎的临床和组织病理学预测因子。

Clinical and histopathologic predictors of recurrent glomerulonephritis after kidney transplantation.

机构信息

Department of Nephrology, Salford Royal hospital, Northern Care Alliance NHS foundation trust, Salford, Manchester, UK.

Faculty of Biology, Medicine and Health, Division of cardiovascular medicine, The University of Manchester, Oxford Road Manchester, UK.

出版信息

Clin Transplant. 2023 Jun;37(6):e14970. doi: 10.1111/ctr.14970. Epub 2023 Mar 23.

Abstract

INTRODUCTION

We evaluated the long-term outcomes of recurrent glomerulonephritis (RGN) using clinical, histopathological, and demographic predictors.

METHODS

A retrospective cohort study of kidney transplant recipients (KTR) in two renal centers between 2005 and 2020. Clinical and native kidney histological data were analyzed. The risk factors and outcomes of each primary glomerulonephritis subtype were assessed using Cox methods.

RESULT

336 recipients with primary glomerulonephritis were analyzed. RGN was diagnosed in 17%, 20%, 25%, and 13% of recipients with IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN) and membranoproliferative glomerulonephritis (MPGN), respectively. Median time to recurrence was shortest in FSGS (.6 years IQR .2-2.9) and longest in MN (6.3 years IQR 3.3-8.0) whereas time to graft loss after diagnosis was shortest in MPGN (.3 years IQR .1-1.7) and longest in IgAN (2.9 year IQR 1.3-4.3). Recipients with recurrent IgAN were likely to be younger, have higher proteinuria at diagnosis, receive living donor allografts, receive cyclosporine treatment, have a history of acute rejection, and have segmental sclerosis in native glomeruli. Younger age of the donors, higher proteinuria at diagnosis, alemtuzumab, proteinuria within the first 12 months, acute rejection, low baseline eGFR, mesangial proliferation, and IgG and IgA deposits were associated with FSGS recurrence. MPGN recurrence was predicted by lower BMI at transplantation, and crescentic native disease. Death-censored graft survival at 5-, 10-, and 15-years was 83%, 51%, and 29% in the RGN group and 95%, 93%, and 84%, respectively in the non-RGN group. Over 15 years, recipients with RGN are nine times more likely than those without RGN to lose their grafts, regardless of donor type, acute rejection, and baseline eGFR. Transplant recipients of related donor allograft were not more likely to have recurrent GN than non-related donors.

摘要

简介

我们评估了使用临床、组织病理学和人口统计学预测因子的复发性肾小球肾炎(RGN)的长期结局。

方法

这是一项回顾性队列研究,纳入了 2005 年至 2020 年间在两个肾脏中心接受肾移植的患者。分析了临床和供体肾脏组织学数据。使用 Cox 方法评估了每种原发性肾小球肾炎亚型的危险因素和结局。

结果

336 名患有原发性肾小球肾炎的患者被纳入分析。IgA 肾病(IgAN)、局灶节段性肾小球硬化(FSGS)、膜性肾病(MN)和膜增生性肾小球肾炎(MPGN)患者中 RGN 的诊断率分别为 17%、20%、25%和 13%。FSGS 患者的复发中位时间最短(0.6 年 IQR.2-2.9),MN 患者的复发中位时间最长(6.3 年 IQR 3.3-8.0),而 MPGN 患者的诊断后移植肾丢失中位时间最短(0.3 年 IQR.1-1.7),IgAN 患者的诊断后移植肾丢失中位时间最长(2.9 年 IQR 1.3-4.3)。复发性 IgAN 患者更可能年轻、诊断时蛋白尿更高、接受活体供体移植、接受环孢素治疗、有急性排斥反应史且有局灶性肾小球硬化。供体年龄较小、诊断时蛋白尿较高、阿仑单抗、12 个月内蛋白尿、急性排斥反应、基线 eGFR 较低、系膜增生和 IgG 和 IgA 沉积与 FSGS 复发相关。移植物蛋白丢失率在 5 年、10 年和 15 年分别为 83%、51%和 29%,而非 RGN 组分别为 95%、93%和 84%。在 15 年期间,无论供体类型、急性排斥反应和基线 eGFR 如何,有 RGN 的患者比没有 RGN 的患者丢失移植物的可能性高 9 倍。与非亲缘供体相比,接受亲缘供体移植的患者发生复发性 GN 的可能性并不高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验